Company news
Atlas Energy Corp. (TSXV:ATLE) news
Atlas Energy Corp. news releases on 6ix. Latest, Sep 25, 2026: Atlas Energy Corp Completes C$15.0 Million Royalty Investment and Receives Approval to Exit…
Press releases & updates
Atlas Energy Corp Completes C$15.0 Million Royalty Investment and Receives Approval to Exit TSXV Sandbox
September 25, 2026
Atlas Energy Corp Reports Second Quarter 2026 Financial Results
August 13, 2026
Atlas Energy Corp. Announces Annual General and Special Meeting Voting Results
August 5, 2026
Atlas Energy Corp. Announces Appointments to Subsidiary Board and Extension of TSXV Sandbox Exit Deadline
June 22, 2026
Atlas Energy Reports First Quarter 2026 Financial Results
May 13, 2026
Atlas Energy Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Operations and Filing of Its 2025 AIF
April 5, 2026
Atlas Energy Reports Third Quarter 2025 Financial Results
November 14, 2025
ATLAS ENERGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
August 28, 2025
ATLAS ENERGY STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF ANDY DUNCAN AS SENIOR EXECUTIVE
August 1, 2025
WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF TRANSFORMATIVE RECAPITALIZATION TRANSACTIONS TO FORM ATLAS ENERGY CORP.
June 19, 2025
WILLOW BIOSCIENCES INC. ANNOUNCES CONDITIONAL ACCEPTANCE OF TSX VENTURE EXCHANGE TO LIST PURSUANT TO THE TSXV SANDBOX
June 16, 2025
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
May 12, 2025
WILLOW BIOSCIENCES INC. RECEIVES FIRM COMMITMENTS OF $30.0 MILLION UNDER PREVIOUSLY ANNOUNCED RECAPITALIZATION FINANCING
May 8, 2025
WILLOW BIOSCIENCES INC. ANNOUNCES $30.0 MILLION RECAPITALIZATION FINANCING AND PROPOSED APPOINTMENT OF NEW EXECUTIVE TEAM AND BOARD OF DIRECTORS TO FORM ATLAS ENERGY CORP.
May 7, 2025
WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
April 30, 2025
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
April 25, 2025
WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
March 25, 2025
WILLOW ANNOUNCES SALE OF OPERATING SUBSIDIARY
March 14, 2025
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
January 20, 2025
WILLOW ANNOUNCES CANCELLATION OF PREVIOUSLY ANNOUNCED NON-BROKERED OFFERING TO PURSUE LESS DILUTIVE ALTERNATIVES
January 2, 2025
WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION
November 18, 2024
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
November 12, 2024
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
November 7, 2024
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
September 18, 2024
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
September 5, 2024
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
August 12, 2024
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
August 7, 2024
WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS
July 18, 2024
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM
June 26, 2024
Willow Bioscience Announces 3 Million dollar Fundraising to Support Partnership with Laurus Labs
June 7, 2024
WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLION
June 3, 2024
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
May 30, 2024
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
May 13, 2024
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
March 28, 2024
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
February 29, 2024
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
February 20, 2024
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
January 31, 2024
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
January 16, 2024
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
January 10, 2024
Willow Bioscience plans to advance development program with Nasdaq-listed company
December 11, 2023
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
December 7, 2023
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
November 14, 2023
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
October 10, 2023
Willow Bioscience teams again with Suanfarma on large volume anti-infective API
October 5, 2023
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
October 3, 2023
Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid
September 12, 2023
WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING
September 12, 2023
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
September 6, 2023
Willow Bioscience files patent to help reduce costs of corticosteroids
September 4, 2023
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST
August 30, 2023